.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

In-person and virtual events just for HCPs

SpecialtySee All >

Breast Cancer
Lung Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Ovarian Cancer
Prostate Cancer
Melanoma & Skin Cancer
MCL
MPN
CAR T-cell Therapy
Chronic Lymphocytic Leukemia
Gynecologic Oncology
Hematologic Oncology
Immuno-Oncology
Multiple Myeloma
Urothelial Cancer

Advertise
About OncLive
Editorial Board
MJH Life Sciences brands
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Evolving Practice Patterns for Advanced Clear Cell Renal Cell Carcinoma

EP. 1: Introduction and Review of CheckMate 9ER for Metastatic RCC

October 23rd 2020

EP. 2: Review of the COSMIC 021 Study for mRCC

October 23rd 2020

EP. 3: Role of TKI After Progression on I/O for mRCC

October 23rd 2020

EP. 4: I/O Therapy After Progression on I/O for mRCC

October 23rd 2020

EP. 5: Upcoming Combination Trials for mRCC

October 23rd 2020

EP. 6: Clinical Trials for Relapsed/Refractory mRCC

October 23rd 2020

EP. 7: Sequencing After Frontline I/O Based Regimen for mRCC

October 23rd 2020

EP. 8: Emerging Agents for Progressive mRCC

October 23rd 2020

EP. 9: Additional Emerging Therapies for Progressive mRCC

October 23rd 2020

EP. 10: Final Thoughts on the Management of mRCC

October 23rd 2020